Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.
You may also be interested in...
Overwhelming votes against existing labels for the antibiotics likely means sponsors and FDA have some safety planning to do.
Adequacy of data on risks of hypersensitivity/anaphylaxis and cardiac dysrhythmia with neuromuscular blockade reversal agent are focus of FDA advisory committee review.
Nothing has been heard about the major depressive disorder treatment since FDA issued a third “not approvable” letter in 2007; advisory committee to discuss NDA in December.